The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Efficacy of troglitazone on body fat distribution in type 2 diabetes.
Open accessAbstract
OBJECTIVE: The insulin-sensitizing action of troglitazone may be mediated through the activation of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) and the promotion of preadipocyte differentiation in adipose tissue on which troglitazone has depot-specific effects. We investigated the relationship between efficacy of the drug and body fat distribution. Changes in body fat distribution were also investigated by long-term administration of the drug. RESEARCH DESIGN AND METHODS: Troglitazone was given at a dose of 400 mg/day to 20 patients with type 2 diabetes whose diet and sulfonylurea therapy produced unsatisfactory glycemic control (HbA(1c) >7.8%) and whose insulin secretory capacity was found to be preserved (postprandial C-peptide >3 ng/ml). HbA(1c) values, serum lipid levels, and body weight were measured monthly Body fat distribution was evaluated in subcutaneous (SC) and visceral fat using a computed tomography scan at umbilical levels before and after troglitazone therapy RESULTS: During the 1-year troglitazone treatment, HbA(1c) was significantly decreased (from 9.2 +/- 0.2 to 7.1 +/- 0.2%, P < 0.01), showing lowest values at 4-6 months, whereas body weight was significantly increased (BMI 24.6 +/- 0.6 to 25.7 +/- 0.6 kg/m2, P < 0.01). Reduction of HbA(1c) (deltaHbA(1c)) from the baseline value during treatment was significantly greater in obese patients (BMI >26 kg/m2) than in nonobese patients (-3.2 +/- 0.4 vs. -2.1 +/- 0.3%, P < 0.05) and was more significant in women than in men (-3.2 +/- 0.2 vs. - 1.4 +/- 0.2%, P < 0.01). The level of deltaHbA(1c) during treatment showed a significant negative correlation with SC fat area (r = -0.742, P < 0.01) but not with visceral fat area. Weight gain during troglitazone treatment resulted in increased accumulation of SC fat without a change in visceral fat area and, consequently. in a significant decrease in the visceral-to-SC fat ratio. CONCLUSIONS: Predominant accumulation of SC fat for the visceral fat tissue was an important predictor of the efficacy of troglitazone therapy in patients with type 2 diabetes. Greater efficacy of troglitazone was observed in women who were characterized by more accumulation of SC adipose tissue than men. Long-term administration of the drug resulted in weight gain with increased accumulation of SC adipose tissue, probably because of the activation of PPAR-gamma in the region.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Enzi, G., Gasparo, M., Biondetti, P., Fiore, D., Semisa, M., & Zurlo, F. (1986) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/44.6.739 · Cited by 547
Effect of troglitazone on body fat distribution in type 2 diabetic patients.
Mori, Y., Murakawa, Y., Okada, K., Horikoshi, H., Yokoyama, J., Tajima, N., & Ikeda, Y. (1999) · Diabetes Care · doi:10.2337/diacare.22.6.908 · Cited by 281
Cited by
Gluteofemoral body fat as a determinant of metabolic health
Manolopoulos, K. N., Karpe, F., & Frayn, K. N. (2010) · International Journal of Obesity · doi:10.1038/ijo.2009.286 · Cited by 811
Mayerson, A. B., Hundal, R. S., Dufour, S., Lebon, V., Befroy, D., Cline, G. W., Enocksson, S., Inzucchi, S. E., Shulman, G. I., & Petersen, K. F. (2002) · Diabetes · doi:10.2337/diabetes.51.3.797 · Cited by 647
Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone.
Wilson-Fritch, L., Nicoloro, S., Chouinard, M., Lazar, M. A., Chui, P. C., Leszyk, J., Straubhaar, J., Czech, M. P., & Corvera, S. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21752 · Cited by 616
RAVUSSIN, E., & SMITH, S. R. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04292.x · Cited by 462
PPARgamma in Metabolism, Immunity, and Cancer: Unified and Diverse Mechanisms of Action
Hernandez-Quiles, M., Broekema, M. F., & Kalkhoven, E. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.624112 · Cited by 433
Metadata
- Authors
- Akazawa, S., Sun, F., Ito, M., Kawasaki, E., & Eguchi, K.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2000-08-01
- Volume
- 23
- Issue
- 8
- Pages
- 1067-1071
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2107207934
- Cited by
- 171
- References
- 2
- FWCI
- 4.96
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of troglitazone on body fat distribution in type 2 diabetes. https://app.cochat.ai/papers/10.2337/diacare.23.8.1067
- The paper
- Akazawa, S., Sun, F., Ito, M., Kawasaki, E., & Eguchi, K. (2000). Efficacy of troglitazone on body fat distribution in type 2 diabetes. Diabetes Care. https://doi.org/10.2337/diacare.23.8.1067
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.